Coherus Oncology, Inc.

CHRSNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$42.2M

▲ 59.8% YoY

Net Income

$168.0M

▲ 489.4% YoY

EPS

$1.43

▲ 472.0% YoY

Cash

$88.9M

▼ 29.5% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.